KIRKLAND, Quebec, Sept. 19, 2018 (GLOBE NEWSWIRE) — Ortho Regenerative Technologies Inc. (“Ortho RTi” or the “Corporation”) (CSE: ORTH) today announced the appointment of Luc Mainville as Senior Vice President and Chief Financial Officer, with overall responsibility for operational finance, financial reporting, budgeting and strategic planning, as well as helping to manage the Corporation’s relationships and interactions with the investment community. Mr. Mainville succeeds Ortho RTi’s interim CFO, Benedek Simo, who will remain as Corporate Controller.
“We are delighted to have Luc join Ortho RTi at this important time in its corporate and clinical development,” said Brent Norton, President and CEO, Ortho RTi. “Being able to attract someone of Luc’s caliber to this role is a clear testament to the quality of our science and the potential market opportunity for our products under development. His significant operational experience will be a particularly valuable asset as we implement the last phase of our pre-IND program and pursue joint development initiatives with interested industry players for our lead product, Ortho-R.”
Mr. Mainville has an accomplished history of financial and operational leadership successes within the life science industry. In an executive management career that spans more than 20 years, he has led or been integrally involved in four go-public transactions, completed more than 20 public financings, and managed more than 50 licensing, merger and acquisition, and sale transactions. Mr. Mainville also serves as Senior Vice President and CFO for Valeo Pharma. His earlier experience includes senior management and financial roles at various life science companies, including Acerus Pharma, Cardiome Pharma Corp., Neopharm Labs Inc. and LAB Research Inc. Prior to launching his career in the life science industry, Mr. Mainville was a Partner at KPMG LLP. Mr. Mainville has served as Vice-Chairman of BIOTECanada and holds an MBA from McGill University. 
About Ortho Regenerative technologies Inc.
Ortho RTi is an emerging Orthopaedic and Sports Medicine technology company dedicated to the development of novel therapeutic soft tissue repair technologies to dramatically improve the success rate of sports medicine surgeries. Our proprietary biopolymer has been specifically designed to increase the healing rates of sports related injuries to ligaments, tendons and cartilage. The polymer can be directly placed into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention. Further information about Ortho RTi is available on the Company’s website at www.orthorti.com and on SEDAR at www.sedar.com.
Caution regarding forward-looking statements
This news release may contain certain forward-looking statements regarding the Corporation’s expectations for future events. Such expectations are based on certain assumptions that are founded on currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could cause actual results to differ include, amongst others, uncertainty as to the final result and other risks. The Corporation disclaims any intention or obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise, other than as required by security laws.
For further Information, please contact:
Stephen Kilmer
Investor & Media Relations
647.872.4849
kilmer@orthorti.com